loading page

An acute lymphoblastic leukemia cell-based preclinical assay revealed functional differences of commercial L-asparaginase administered in Colombia
  • +4
  • Diego Fernando Rincón Reyes,
  • José Luis Padilla Agudelo,
  • Andrea Isabel Pinilla Da Silva,
  • Diana Marcela Ortega Quintero,
  • Diana Lorena Valencia Libreros,
  • Agustin Contreras Acosta,
  • José Arturo Gutiérrez Triana
Diego Fernando Rincón Reyes
Universidad Industrial de Santander Facultad de Salud
Author Profile
José Luis Padilla Agudelo
Universidad Industrial de Santander Facultad de Salud
Author Profile
Andrea Isabel Pinilla Da Silva
Universidad Industrial de Santander Facultad de Salud
Author Profile
Diana Marcela Ortega Quintero
Universidad Industrial de Santander Facultad de Salud
Author Profile
Diana Lorena Valencia Libreros
Asociación Colombiana de Hematología y Oncología Pediátrica (ACHOP)
Author Profile
Agustin Contreras Acosta
Asociación Colombiana de Hematología y Oncología Pediátrica (ACHOP)

Corresponding Author:[email protected]

Author Profile
José Arturo Gutiérrez Triana
Universidad Industrial de Santander Facultad de Salud
Author Profile

Abstract

L-asparaginase (L-ASNase) is an essential component of chemotherapy schemes due to its differential action over normal and leukemic cells. Recently, concerns on the performance of commercial formulations administered in developing countries have been reported. To address this problem, we developed a cell-based protocol to compare the activity of different L-ASNase formulations used in Colombia. We found three statistically different groups, ranging from full to no activity on leukemic cells using 0.05, 0.5 and 5.0 IU/mL concentrations. According to our results, we advise a preclinical evaluation for formulations of L-ASNase distributed in developing countries which could impact the outcome of patients.
01 Sep 2022Submission Checks Completed
01 Sep 2022Assigned to Editor
01 Sep 2022Submitted to Pediatric Blood & Cancer
21 Oct 2022Review(s) Completed, Editorial Evaluation Pending
22 Oct 2022Reviewer(s) Assigned
07 Nov 2022Editorial Decision: Revise Minor
30 Nov 20221st Revision Received
30 Nov 2022Submission Checks Completed
30 Nov 2022Assigned to Editor
30 Nov 2022Review(s) Completed, Editorial Evaluation Pending
05 Dec 2022Reviewer(s) Assigned
19 Dec 2022Editorial Decision: Accept